Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.

被引：4
|
作者：
Ohtsu, Atsushi
Tabernero, Josep
Bang, Yung-Jue
Fuchs, Charles S.
Sun, Linda
Wang, Zhen
Csiki, Ildiko
Koshiji, Minori
Van Cutsem, Eric
机构：
[1] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Merck & Co Inc, Kenilworth, NJ USA
[6] MSD China, Beijing, Peoples R China
[7] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps183
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS183
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Randomized, open-label, phase 3 KEYNOTE-061 study
    Ohtsu, A.
    Tabernero, J.
    Bang, Y. -J.
    Fuchs, C.
    Sun, L.
    Wang, Z.
    Csiki, I.
    Koshiji, M.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2015, 26
  • [2] Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.
    Ohtsu, Atsushi
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Sun, Linda
    Wang, Zhen
    Csiki, Ildiko
    Koshiji, Minori
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Ohtsu, A.
    Tabernero, J.
    Bang, Y. -J.
    Fuchs, C. S.
    Sun, L.
    Wang, Z.
    Csiki, I.
    Koshiji, M.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2015, 26 : 69 - 69
  • [4] KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma
    Yoon, H.
    Fuchs, C.
    Ozguroglu, M.
    Bang, Y.
    Di Bartolomeo, M.
    Mandala, M.
    Ryu, M.
    Fornaro, L.
    Olesinski, T.
    Caglevic, C.
    Chung, H.
    Muro, K.
    Van Cutsem, E.
    Elme, A.
    Thuss-Patience, P.
    Chau, I.
    Ohtsu, A.
    Wang, A.
    Bhagia, P.
    Lin, J.
    Shih, C.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S236 - S236
  • [5] Pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Multicohort phase II KEYNOTE-059 study.
    Fuchs, Charles S.
    Denker, Andrew E.
    Tabernero, Josep
    Van Cutsem, Eric
    Ohtsu, Atsushi
    Lam, Baohoang
    Koshiji, Minori
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [6] KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
    Shitara, K.
    Ozguroglu, M.
    Bang, Y. J.
    Di Bartolomeo, M.
    Mandala, M.
    Ryu, M. H.
    Fornaro, L.
    Olesinski, T.
    Caglevic, C.
    Chung, H.
    Muro, K.
    Gokkurt, E.
    Mansoor, W.
    McDermott, R.
    Schacham-Shmueli, E.
    Chen, X.
    Kang, S. P.
    Mayo, C.
    Ohtsu, A.
    Fuchs, C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Fuchs, Charles S.
    Denker, Andrew E.
    Tabernero, Josep
    Van Cutsem, Eric
    Ohtsu, Atsushi
    Lam, Baohoang
    Koshiji, Minori
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Kher, Uma
    Lam, Baohoang
    Koshiji, Minori
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [9] Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
    Van Cutsem, Eric
    Amonkar, Mayur
    Fuchs, Charles S.
    Alsina, Maria
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Chung, Hyun Cheol
    Muro, Kei
    Goekkurt, Eray
    Benson, Al B., III
    Sun, Weijing
    Wainberg, Zev A.
    Norquist, Josephine M.
    Chen, Xinqun
    Shih, Chie-Schin
    Shitara, Kohei
    GASTRIC CANCER, 2021, 24 (06) : 1330 - 1340
  • [10] Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
    Eric Van Cutsem
    Mayur Amonkar
    Charles S. Fuchs
    Maria Alsina
    Mustafa Özgüroğlu
    Yung-Jue Bang
    Hyun Cheol Chung
    Kei Muro
    Eray Goekkurt
    Al B. Benson
    Weijing Sun
    Zev A. Wainberg
    Josephine M. Norquist
    Xinqun Chen
    Chie-Schin Shih
    Kohei Shitara
    Gastric Cancer, 2021, 24 : 1330 - 1340
12345